Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A2A antagonist istradefylline PET study in methamphetamine use disorder (A2D2-S)
jRCTs031200330Completed
- Sponsor
- Japan Society for the Promotion of Science
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of Istradefylline in methamphetamine use disorder (MUD) and stimulant use disorder (SUD), sponsored by Japan Society for the Promotion of Science. Primary endpoint: Striatal dopamine D2 receptor availability. Started Oct 2021; status: completed.
02
Drugs
Istradefylline
03
Conditions
methamphetamine use disorder (MUD)stimulant use disorder (SUD)
Beyond the preview
Go deeper on jRCTs031200330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200330.